2,2,2-Trichloroethyl chloroformate

We are 2,2,2-Trichloroethyl chloroformate CAS:17341-93-4 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:   2,2,2-Trichloroethyl chloroformate
CAS.NO: 17341-93-4
Synonyms:
2,2,2'4',5'-PENTACHLOROACETOPHENONE
Trichloroethyl chloroformate
trichloroethoxycarbonyl chloride
2,2,2-trichloroethyl chlorocarbonate
Chloroformic Acid 2,2,2-Trichloroethyl Ester
2,2,2-Trichloroethylchloroformate
Carbonochloridic acid, 2,2,2-trichloroethyl ester
2,2,2-trichloroethoxycarbonyl chloride

Molecular Formula: C3H2Cl4O2
Molecular Weight: 211.85900

Physical and Chemical Properties:
Density: 1.539 g / mL at 25 ° C (lit.)
Boiling point: 171-172 ° C (lit.)
Melting point: 1 ° C
Flash point:> 100 ° C
Refractive index: n20 / D 1.471 (lit.)

Specification:
Appearance: Colorless Transparent Liquid
Purity:≥98%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage: 2-8ºC.Keep away from heat, sparks, and flame. Keep away from sources of ignition. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Application:
Intermediates of Naltrexone CAS: 16590-41-3

Related News: Oligomannate, which uses extract from marine brown algae as raw material, received a conditional green light to treat mild-to-moderate level AD, the National Medical Products Administration (NMPA) said in a statement on its website late on Saturday.2-metil-3-nitrobenzotrifluoruro CAS:6656-49-1 Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).5-Amino-2-Bromo-3-Methylpyridine CAS:38186-83-3 Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).3-pyridinecarbonitrile CAS:100-54-9 It does not require a production license for the drug substance, and can be produced in an ordinary chemical plant. As long as it reaches a certain level, it can be used for the synthesis of the drug substance.With the structural upgrade of the pharmaceutical industry in developed countries, the transfer of related industrial chains has taken place globally, and it has also had a profound impact on Chinese pharmaceutical companies. near